Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be unaffected.

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately $14.7 billion, up about 30% YoY, and adjusted EPS of $5.

It comes as President Donald Trump pressures drugmakers to lower U.S. drug prices while hiking them abroad under a policy called "most favored nation."